# Study of NIB101 in Participants With Advanced Solid Tumors

> **NCT05192174** · PHASE1 · TERMINATED · sponsor: **Noile-Immune Biotech, Inc** · enrollment: 3 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** NIB101

## Key facts

- **NCT ID:** NCT05192174
- **Lead sponsor:** Noile-Immune Biotech, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-24
- **Primary completion:** 2025-05-16
- **Final completion:** 2025-05-16
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** due to the reconsideration of development strategy
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192174, "Study of NIB101 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05192174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*